Skip to content

FELICITA - A proof of concept study: open label phase IIa trial evaluating the effect and safety of transplantation of fecal microbiota in children with autism spectrum disorders and gastrointestinal symptoms

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-520539-17-00
Acronym
APHP241418
Enrollment
5
Registered
2025-05-07
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Austistic spectrum disorder

Brief summary

Rate of children with a success, determined by the reduction of more than 50% of the composite score in the Gastrointestinal Symptoms Rating Scale (GSRS) evaluated by parents between inclusion and week 18. GSRS is validated in French and evaluates the intensity of 5 gastrointestinal symptoms (diarrhea, abdominal pain, constipation, indigestion, and reflux).

Detailed description

Improvement on autistic core symptoms and global improvement [at W0, W4, W18, W24, M12] by multiples questionnaires and scales, FMT side effects (antibiotic therapy, GM transplantation from a healthy donor): Pediatric Adverse Event Rating Scale [evaluated by the pediatrician at day (D) 0, D5, W4, W18, W24, M12], Adherence to instruction to be followed during the FMT process, drop out numbers, reasons of drop out, acceptability questionnaire - Stool consistency: Bristol Stool Form Scale [by parents from W0 to W4 and from W17 to W18] and global improvement: Caregiver Strain index [by a psychologist at W0, W4, W18, W24, M12], Pediatric Quality of Life Inventory (PedsQL) [at W0, W18, M12]

Interventions

DRUGEnema transplant of fecal microbiota 25g/100mL

Sponsors

Assistance Publique Hopitaux De Paris
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
Rate of children with a success, determined by the reduction of more than 50% of the composite score in the Gastrointestinal Symptoms Rating Scale (GSRS) evaluated by parents between inclusion and week 18. GSRS is validated in French and evaluates the intensity of 5 gastrointestinal symptoms (diarrhea, abdominal pain, constipation, indigestion, and reflux).

Secondary

MeasureTime frame
Improvement on autistic core symptoms and global improvement [at W0, W4, W18, W24, M12] by multiples questionnaires and scales, FMT side effects (antibiotic therapy, GM transplantation from a healthy donor): Pediatric Adverse Event Rating Scale [evaluated by the pediatrician at day (D) 0, D5, W4, W18, W24, M12], Adherence to instruction to be followed during the FMT process, drop out numbers, reasons of drop out, acceptability questionnaire - Stool consistency: Bristol Stool Form Scale [by parents from W0 to W4 and from W17 to W18] and global improvement: Caregiver Strain index [by a psychologist at W0, W4, W18, W24, M12], Pediatric Quality of Life Inventory (PedsQL) [at W0, W18, M12]

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026